BRIEF RESEARCH REPORT article

Front. Genet., 16 September 2020

Sec. Applied Genetic Epidemiology

Volume 11 - 2020 | https://doi.org/10.3389/fgene.2020.540724

The Role of Genetically Determined Glycemic Traits in Breast Cancer: A Mendelian Randomization Study

  • 1. Translational Sciences Section, Jonsson Comprehensive Cancer Center, School of Nursing, University of California, Los Angeles, Los Angeles, CA, United States

  • 2. Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

  • 3. Center for Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, CA, United States

  • 4. Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, United States

  • 5. Department of Epidemiology, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA, United States

  • 6. Center for Human Nutrition, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, United States

Abstract

Background:

Circulating glycemic traits (GTs) have been considered a risk factor for breast cancer, but studies using GT-associated genetic variants as an instrumental variable are limited and inconclusive.

Methods:

Our Mendelian Randomization analysis used the most recent genome-wide datasets focusing on European women.

Results:

Of 44 single-nucleotide polymorphisms (SNPs) with GTs, 38 fasting-glucose and 6 fasting-insulin SNPs showed heterogeneous associations with breast cancer, without significant directional pleiotropy observed.

Conclusion:

Our findings indicate a null association between genetically determined GTs and breast cancer risk among European women. Our findings may contribute to more complete characterizing of metabolic pathways in GTs and breast cancer.

Introduction

Previous studies for circulating glycemic traits (GTs), including fasting glucose (FG) and insulin (FI) concentrations, have shown inconsistent associations with breast cancer development (Gunter et al., 2009; Sieri et al., 2012; Boyle et al., 2013; Hernandez et al., 2014). This is partially due to selection bias, confounding, short time exposure to such metabolic biomarkers, measurement errors, and reverse causation. We tried to address those challenges by using a 2-sample Mendelian Randomization (MR) approach and examined whether genetically determined GTs are causally associated with breast cancer risk. The MR method may provide a relatively unbiased causal relationship between phenotype and cancer outcome because it reduces potential bias and confounding and prevents reverse causation by the random assortment of alleles at meiosis, resulting in random assignment of exposure, which precedes the phenotype and clinical outcomes (Merino et al., 2017).

Materials and Methods

For the GT instrumental variables, we used the recently updated publicly available data in 2019 from genome-wide association studies (GWASs) of the Meta-Analysis of Glucose and Insulin-related traits Consortium (MAGIC) in non-diabetic European women1. Detailed rationale and design of the studies have been described elsewhere (Scott et al., 2012). For breast cancer outcomes, we pulled 4 datasets from 2 independent consortia: Breast Cancer Association Consortium (BCAC2): (i) OncoArray; the Atlas of GWAS Summary Statistics (ATLAS3): (ii) CGEMS Breast Cancer GWAS, (iii) GEE adjusted for age, and (iv) GEE for age and body mass index. Study participants from each dataset provided written informed consent. Genetic instruments for each dataset were single-nucleotide polymorphisms (SNPs) associated with the trait at the genome-wide level (p < 5E-08).

We performed MR analysis using the inverse-variance weighted method (Burgess et al., 2013) which quantifies the genetically determined association between GTs and breast cancer risk. We assume that summarized data are available for multiple genetic variants in relation to the risk factor of interest X and the outcome Y; genetic variant k, k = 1,…, K is associated with an observed Xk mean change in the risk factor per additional variant allele with standard error σXk and an observed Yk changes in the log-odds or the log-probability of an outcome per allele with standard error σYk. The inverse-variance weighted estimates combine the ratio estimates from each variant in a fixed-effect meta-analysis model:

The approximate standard error of the estimate is:

The results were reported as risk ratios and 95% confidence intervals for the change in breast cancer risk per unit increase in FG (mmol/L) or natural log-transformed FI (pmol/L). To determine the extent of pleiotropic signal, we applied Cochran’s Q test and the MR-Egger analysis. Given obesity and diabetes’s established role for breast cancer, we excluded those relevant SNPs from the analysis. R3.6.1 was used. The Institutional Review Board of the University of California, Los Angeles, approved this study.

Results and Discussion

Of 430 GWA-based SNPs related to GTs in MAGIC, 44 SNPs within linkage disequilibrium (r2 < 0.1) were matched to either BCAC or ATLAS datasets (Table 1). The 38 FG-SNPs overall and stratified by cancer data source showed heterogeneous results but mostly showed a slightly increased effect on breast cancer risk without reaching statistical significance (Table 2 and Figure 1). After excluding top GWA-SNPs associated with type 2 diabetes and visceral obesity, the directions of the associations between GTs and breast cancer were changed in OncoArray but not in ATLAS-CGEMS. The 6 FI-SNPs showed similar patterns for the associations with breast cancer. No significant directional pleiotropy was observed (Table 3).

TABLE 1

Gene*SNPChrPositionAlleleAlt allele frequencyPhenotypeBreast cancer¥



Ref/AltEffect sizepOR95% CIp
Fasting glucose Breast cancer: OncoArray
PROX1rs3408741214159256T/C0.5620.0201.69E-130.982(0.969–0.994)0.004
G6PC2rs5608872169763148T/C0.6740.0678.08E-920.994(0.980–1.008)0.389
GCKRrs780094227741237T/C0.6060.0313.06E-261.012(0.999–1.024)0.070
ADCY5rs117080673123065778G/A0.7740.0275.01E-161.004(0.989–1.018)0.644
SLC2A2rs119246483170717996G/A0.8630.0291.74E-110.985(0.968–1.003)0.104
PCSK1rs7713317595716722G/A0.6950.0236.50E-140.995(0.981–1.009)0.476
AC006045.3rs1558318715065612T/A0.5450.0282.93E-201.003(0.991–1.016)0.595
GCKrs4607517744235668G/A0.1950.0582.66E-461.000(0.982–1.017)0.959
SLC30A8rs38021778118185025G/A0.2390.0341.12E-270.984(0.971–0.997)0.016
PPP1R3Brs98330989177732T/G0.9030.0324.85E-131.020(1.000–1.040)0.050
GLIS3rs1081491694293150C/A0.4340.0197.61E-101.006(0.993–1.019)0.372
CDKN2B-AS1rs2383208922132076G/A0.7920.0261.19E-130.986(0.970–1.001)0.070
ADRA2Ars1119550210113039667T/C0.9250.0357.41E-121.020(0.998–1.042)0.080
TMEM258rs1022751161557803T/C0.3510.0191.01E-090.993(0.981–1.006)0.292
MTNR1Brs108309631192708710G/C0.7000.0741.36E-980.992(0.978–1.007)0.284
CTD-2210P24.6rs64856441145855998T/C0.5310.0191.39E-100.991(0.979–1.003)0.154
MADDrs79445841147336320T/A0.7120.0242.20E-121.031(1.016–1.045)<0.001
PDX1rs116193191328487599G/A0.7880.0219.26E-101.003(0.989–1.018)0.662
VPS13C/C2CD4A/Brs45021561562383155T/C0.4200.0233.07E-151.016(1.003–1.030)0.014
FG, Breast cancer: ATLAS-CGEMS
PROX1rs3408741214159255T/C0.5620.0201.69E-130.991(0.819–1.198)0.913
G6PC2rs5608872169763147T/C0.6740.0678.08E-921.006(0.846–1.196)0.745
GCKRrs780094227741236T/C0.6060.0313.06E-260.994(0.828–1.193)0.983
RNU1-70Prs117091403170694496T/C0.1370.0261.90E-090.937(0.769–1.140)0.435
ADCY5rs28777163123094450T/C0.7520.0237.27E-111.029(0.865–1.225)0.919
PCSK1rs4869272595539447T/C0.3230.0221.64E-131.070(0.900–1.272)0.721
AC006045.3rs2191348715064254T/G0.4820.0262.56E-181.000(0.827–1.208)1.000
GCKrs4607517744235667G/A0.1950.0582.66E-460.918(0.762–1.105)0.207
SLC30A8rs132666348118184782T/C0.7610.0306.72E-211.015(0.852–1.208)0.467
PPP1R3Brs98330989177731T/G0.9030.0324.85E-130.971(0.783–1.203)0.937
GLIS3rs1081491694293149C/A0.4340.0197.61E-100.999(0.823–1.213)0.999
CDKN2B-AS1rs2383208922132075G/A0.7920.0261.19E-131.065(0.886–1.278)0.039
BTBD7P2rs425831310113032397T/G0.9140.0371.82E-111.027(0.827–1.275)0.625
TMEM258rs1022751161557802T/C0.3510.0191.01E-091.029(0.865–1.225)0.768
CRY2rs116078831145839708G/A0.4690.0181.86E-101.006(0.829–1.219)0.967
ACP2rs119881147261259G/A0.3720.0215.07E-120.916(0.765–1.095)0.412
MTNR1Brs13871531192673827T/C0.7280.0541.27E-580.954(0.803–1.134)0.619
PDX1-AS1rs22939411328491197G/A0.2120.0211.42E-091.101(0.923–1.312)0.470
NPM1P47rs71724321562396388G/A0.5800.0233.15E-110.888(0.739–1.068)0.448
FG, Breast cancer: ATLAS-GEEA
PROX1-AS1rs14319851214148245G/A0.3270.0191.15E-090.989(0.964–1.016)0.427
SNX17rs1528533227595755G/C0.4580.0185.29E-090.988(0.962–1.016)0.406
ABCB11rs4948742169789305T/C0.6280.0531.82E-681.004(0.976–1.034)0.771
SLC2A2rs105136863170725541G/A0.1420.0273.73E-101.003(0.968–1.039)0.878
AC006045.3rs10487796715063429T/A0.5250.0278.54E-200.980(0.954–1.007)0.140
BTBD7P2rs1050993810113028616T/C0.9200.0353.18E-111.016(0.961–1.073)0.580
MADDrs105013201147293798G/C0.2920.0223.47E-081.004(0.975–1.034)0.808
MTNR1Brs13871531192673827T/C0.7280.0541.27E-581.020(0.987–1.054)0.230
FADS2rs15351161597971G/A0.6590.0192.75E-091.013(0.983–1.044)0.405
FG, Breast cancer: ATLAS-GEEAB
PROX1-AS1rs14319851214148245G/A0.3270.0191.15E-090.990(0.964–1.016)0.441
SNX17rs1528533227595755G/C0.4580.0185.29E-090.988(0.961–1.016)0.399
ABCB11rs4948742169789305T/C0.6280.0531.82E-681.004(0.975–1.033)0.801
SLC2A2rs105136863170725541G/A0.1420.0273.73E-101.001(0.966–1.038)0.941
AC006045.3rs10487796715063429T/A0.5250.0278.54E-200.980(0.954–1.007)0.146
BTBD7P2rs1050993810113028616T/C0.9200.0353.18E-111.014(0.959–1.072)0.624
MADDrs105013201147293798G/C0.2920.0223.47E-081.004(0.975–1.034)0.798
MTNR1Brs13871531192673827T/C0.7280.0541.27E-581.020(0.987–1.055)0.233
FADS2rs15351161597971G/A0.6590.0192.75E-091.013(0.982–1.044)0.413
Fasting insulin Breast cancer: OncoArray
COBLL1rs101791262165511794G/C0.6050.0213.78E-081.008(0.995–1.021)0.208
GCKRrs780093227742603T/C0.6060.0218.48E-091.011(0.999–1.024)0.076
ZNF12/AC073343.13rs779847176744957T/C0.2430.0261.55E-080.997(0.984–1.011)0.680
RP11-115J16.1rs424062489184231G/A0.9250.0381.10E-091.027(1.005–1.050)0.016
FI, Breast cancer: ATLAS-CGEMS
GCKRrs780094227741236T/C0.6060.0211.00E-080.994(0.828–1.193)0.983
ZNF12/AC073343.13rs779847176744956T/C0.2430.0261.55E-081.063(0.895–1.263)0.708
PPP1R3Brs98330989177731T/G0.9030.0322.03E-090.971(0.783–1.203)0.937

Top GWA SNPs associated with glucose-metabolism phenotypes and breast cancer risk.

Alt, alternative allele; Chr, chromosome; CI, confidence interval; CGEMS, Cancer Genetic Markers of Susceptibility Breast Cancer Genome-wide Association (GWA) Study; FG, fasting glucose; FI, fasting insulin; GEEA, generalized estimating equation regression adjusted for age; GEEAB, GEEA additionally adjusted for body mass index; OR, odds ratio; Ref, reference allele; SNP, single-nucleotide polymorphism. Numbers in bold face are statistically significant. *Genes were arranged by GWA data source for breast cancer: OncoArray, ATLAS-CGEMS, ATLAS-GEEA, and ATLAS-GEEAB. Phenotype includes FG and FI; the relevant top SNPs (p < 5E-08) were identified by MAGIC. ¥The SNPs for association with breast cancer risk were pulled from 2 independent consortia (OncoArray and ATLAS [CGEMS; GEEA; and GEEAB]).

TABLE 2

A set of GM-SNPs arranged by breast-cancer data sourceSNPOR95% CIpphat
n
Fasting glucose
OncoArray191.002(0.831–1.209)0.984< 0.001
OncoArray*51.045(0.354–3.081)0.916<0.001
OncoArray – T2DM¥160.981(0.800–1.203)0.843<0.001
OncoArray – T2DM¥*40.808(0.157–4.150)0.706<0.001
ATLAS-CGEMS191.146(0.507–2.592)0.7290.993
ATLAS-CGEMS – T2DM¥161.002(0.400–2.513)0.9960.980
ATLAS-GEEA91.034(0.748–1.429)0.8170.640
ATLAS-GEEAB91.029(0.747–1.416)0.8430.664
FG: Pooled MR381.014(0.889–1.156)0.8300.0007
Fasting insulin
OncoArray41.002(0.417–2.405)0.9950.014
OncoArray –WHR¥30.895(0.202–3.964)0.7790.013
ATLAS-CGEMS33.335(0.147–75.424)0.2380.889
FI: Pooled MR61.003(0.579–1.737)0.9880.056

Mendelian randomization analysis for the effect of genetically determined glucose-metabolism phenotypes on risk for breast cancer.

CI, confidence interval; CGEMS, Cancer Genetic Markers of Susceptibility Breast Cancer Genome-wide Association (GWA) Study; FG, fasting glucose; FI, fasting insulin; GEEA, generalized estimating equation regression adjusted for age; GEEAB, GEEA, additionally adjusted for body mass index; GM, glucose metabolism; MR, Mendelian randomization; OR, odds ratio; SNP, single–nucleotide polymorphism; T2DM, type 2 diabetes; WHR, waist-to-hip ratio. Phat was estimated via Cochran’s Q; by correcting multiple comparisons, the MR results for the following sets of SNPs were statistically heterogeneous: FG-OncoArray; FG-OncoArray*; FG-OncoArray-T2DM¥; FG-OncoArray-T2DM¥*; FG-Pooled MR; and FI-OncoArray-WHR¥. *A subset of the GM-SNPs that are statistically associated with breast cancer (p < 0.05) was included in the analysis. ¥GM-SNPs excluding top GWA-SNPs associated with T2DM or WHR were analyzed to reduce the pleiotropic effect from T2DM or WHR, respectively.

FIGURE 1

TABLE 3

A set of GM-SNPs arranged by breast-cancer data sourceIntercept95% CIp
Fasting glucose
OncoArray1.000(0.993–1.007)0.995
OncoArray*1.004(0.967–1.043)0.743
OncoArray – T2DM¥1.002(0.994–1.009)0.607
OncoArray – T2DM¥*1.010(0.954–1.069)0.533
ATLAS-CGEMS0.994(0.966–1.023)0.683
ATLAS-CGEMS – T2DM¥0.987(0.956–1.020)0.414
ATLAS-GEEA0.999(0.988–1.011)0.863
ATLAS-GEEAB0.999(0.988–1.010)0.830
FG: Pooled MR–Egger1.000(0.995–1.004)0.883
Fasting insulin
OncoArray1.014(0.995–1.034)0.088
OncoArray – WHR¥1.014(0.931–1.103)0.291
ATLAS-CGEMS1.003(0.698–1.442)0.929
FI: Pooled MR–Egger1.014(1.005–1.024)0.015

Mendelian randomization–Egger test results.

CI, confidence interval; CGEMS, Cancer Genetic Markers of Susceptibility Breast Cancer Genome-wide Association (GWA) Study; FG, fasting glucose; FI, fasting insulin; GEEA, generalized estimating equation regression adjusted for age; GEEAB, GEEA additionally adjusted for body mass index; GM, glucose metabolism; MR, Mendelian randomization; SNP, single-nucleotide polymorphism; T2DM, type 2 diabetes; WHR, waist-to-hip ratio. MR–Egger test cannot estimate standard error with a single or 2 SNPs. *A subset of the GM-SNPs that are statistically associated with breast cancer (p < 0.05) was included in the analysis. ¥GM-SNPs excluding top GWA-SNPs associated with T2DM or WHR were analyzed to reduce the pleiotropic effect from T2DM or WHR, respectively.

We analyzed the relatively large and most-updated GWA-datasets for causality between GTs and breast cancer. Given that associations between metabolic markers and breast cancer risk can differ by menopausal status, our findings may be confounded. However, data was not available on the menopausal status, thus warranting future studies that account for this difference. In addition, whereas MR is considered a conservative approach, it may be confounded when modeled SNPs independently affect breast cancer risk through intermediate traits other than GTs.

Our study results should be interpreted with caution because of population structure bias (i.e., results biased due to tagged environmental factors) and unmeasured confounding factors that could have introduced bias. MR analysis might also be subject to non-linearity between exposure and outcome, but potential violation of the linearity assumption tends to bias MR estimates toward the null, rather than generating a spurious association (Smith and Ebrahim, 2003). Moreover, our study may not be generalized to other races or ethnicity, in which the association between genetic instruments, GTs, and breast cancer risk may be different.

Our findings indicate a null association between genetically determined GTs and breast cancer risk among European women. Our study may contribute to more complete characterizing of molecular pathways in GTs and breast cancer. It also highlights the need to conduct a more comprehensive and individual-level analysis using more detailed trait information, including risk causing confusion in this field of research.

Statements

Data availability statement

The datasets generated for this study are available on request to the corresponding author.

Author contributions

SJ, NM, SH, and Z-FZ designed the study. SJ and SH performed the genomic data QC and statistical analysis and interpreted the data. NM and Z-FZ supervised the genomic data QC and analysis and participated in the study coordination and interpreted the data. SJ secured funding for this project. All authors participated in the manuscript writing and editing, read and approved the submission of the manuscript.

Funding

This study was supported by the National Institute of Nursing Research of the National Institutes of Health under Award Number K01NR017852 and a University of California Cancer Research Coordinating Committee grant (CRN-18-522722).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

  • 1

    BoyleP.KoechlinA.PizotC.BoniolM.RobertsonC.MullieP.et al (2013). Blood glucose concentrations and breast cancer risk in women without diabetes: a meta-analysis.Eur. J. Nutr.5215331540. 10.1007/s00394-012-0460-z

  • 2

    BurgessS.ButterworthA.ThompsonS. G. (2013). Mendelian randomization analysis with multiple genetic variants using summarized data.Genet Epidemiol.37658665. 10.1002/gepi.21758

  • 3

    GunterM. J.HooverD. R.YuH.Wassertheil-SmollerS.RohanT. E.MansonJ. E.et al (2009). Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.J. Natl. Cancer Inst.1014860. 10.1093/jnci/djn415

  • 4

    HernandezA. V.GuarnizoM.MirandaY.PasupuletiV.DeshpandeA.PaicoS.et al (2014). Association between insulin resistance and breast carcinoma: a systematic review and meta-analysis.PLoS One9:e99317. 10.1371/journal.pone.0099317

  • 5

    MerinoJ.LeongA.PosnerD. C.PornealaB.MasanaL.DupuisJ.et al (2017). Genetically driven hyperglycemia increases risk of coronary artery disease separately from type 2 diabetes.Diabetes Care40687693. 10.2337/dc16-2625

  • 6

    ScottR. A.LagouV.WelchR. P.WheelerE.MontasserM. E.LuanJ.et al (2012). Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways.Nat. Genet.449911005. 10.1038/ng.2385

  • 7

    SieriS.MutiP.ClaudiaA.BerrinoF.PalaV.GrioniS.et al (2012). Prospective study on the role of glucose metabolism in breast cancer occurrence.Int. J. Cancer130921929. 10.1002/ijc.26071

  • 8

    SmithG. D.EbrahimS. (2003). ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease?Int. J. Epidemiol.32122. 10.1093/ije/dyg070

Summary

Keywords

genetically determined glucose and insulin, breast cancer, Mendelian randomization, obesity, diabetes

Citation

Jung SY, Mancuso N, Han S and Zhang Z-F (2020) The Role of Genetically Determined Glycemic Traits in Breast Cancer: A Mendelian Randomization Study. Front. Genet. 11:540724. doi: 10.3389/fgene.2020.540724

Received

05 March 2020

Accepted

18 August 2020

Published

16 September 2020

Volume

11 - 2020

Edited by

Cheryl Ann Winkler, Frederick National Laboratory for Cancer Research (NIH), United States

Reviewed by

Jing Dong, Baylor College of Medicine, United States; Sarah Buxbaum, Jackson State University, United States

Updates

Copyright

*Correspondence: Su Yon Jung, ;

This article was submitted to Applied Genetic Epidemiology, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics